Nabil F. Saba

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 4.9K citations · Full text

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 776 citations · Full text

Neoadjuvant Therapy, Checkmate 141, Medicine +9

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister et al. · Journal of Clinical Oncology · 2017 · 641 citations · Full text

Neck Cancer, Neoadjuvant Therapy, Cancer Management +20

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein et al. · The Lancet Oncology · 2017 · 417 citations · Full text

Oncology, Neoadjuvant Therapy, Checkmate 141 +11

Adenoid cystic carcinoma of the head and neck

C. L. Ellington, Michael Goodman, Scott A. Kono et al. · Cancer · 2012 · 351 citations · Full text